Sector Expert: Christian Glennie

Edison Investment Research

Image: Christian Glennie

Christian Glennie joined the healthcare team at Edison Investment Research in January 2012 and has 11 years' experience covering the global biotech/pharmaceutical sector as an analyst and a journalist. He came to Edison having held senior analyst and editorial roles at EvaluatePharma and EP Vantage. Christian Glennie also has prior experience as a marketing analyst at Zeneca Agrochemicals.



Recent Quotes

"ATHX's MultiStem in ischemic stroke showed a favorable safety profile."

— Christian Glennie, Edison Investment Research (5/5/15)
more >

"Positive Phase 2 data in ischemic stroke could significantly rerate ATHX stock."

— Christian Glennie, Edison Investment Research (3/5/15)
more >

"We estimate ATHX's MultiStem to hit peak sales of $3B across the US, EU and Japan."

— Christian Glennie, Edison Investment Research (1/12/15)
more >

"ATHX is well positioned in terms of its stage of development and the profile of its MAPCs."

— Christian Glennie, Edison Investment Research (11/24/14)
more >

"Positive Phase 2 data in ischemic stroke could rerate ATHX's stock."

— Christian Glennie, Edison Investment Research (9/24/14)
more >

"ATHX's Phase 2, ischemic stroke study results are expected in Q4/14."

— Christian Glennie, Edison Investment Research (6/30/14)
more >

"Potential FDA clearance for VRS' Aura is a key near-term catalyst."

— Christian Glennie, Edison Investment Research (6/30/14)
more >

"A key, near-term catalyst for VRS is 501(k) FDA clearance for Aura."

— Christian Glennie, Edison Investment Research (6/2/14)
more >



Due to permission requirements, not all quotes are shown.